Esperion Therapeutics

Esperion Files For $70M IPO

The Plymouth-based cholesterol drug developer Esperion Therapeutics Inc. has filed for an initial public stock offering with the federal Securities and Exchange Commission. Esperion is seeking to raise up to $70 million.

WWJ Newsradio 950–2013/05/15

Esperion Reports Cholesterol Cut Up To 43% In Diabetics On New Drug

Esperion Therapeutics’ proposed new cholesterol-busting drug cut the level of low-density lipoprotein, the so-called bad choleterol, up to 43 percent in a Phase 2 test of diabetic patients.

WWJ Newsradio 950–2013/05/02

Esperion Gets $33M To Continue Work On Cholesterol Buster

The Ann Arbor biotech firm Esperion Therapeutics Inc. announced that it has completed a $33 million preferred stock financing led by new investor Longitude Capital.

WWJ Newsradio 950–2013/04/25

Esperion Announces Positive Results From Phase 2 Trial Of Cholesterol Drug In Diabetes Patients

Diabetes patients who took a heart drug canadidate from Esperion Therapeutics, ETC 1002, found their so-called bad choleseterol, LDL-C, fall up to 43 percent, the company reported Monday.

WWJ Newsradio 950–2013/01/07

Tim Mayleben Named President And CEO Of Esperion Therapeutics

Esperion Therapeutics, the leading developer of small molecule therapies for the treatment of cardiometabolic disorders, announced that Tim Mayleben has been named president and CEO of the company.

WWJ Newsradio 950–2013/01/06

HR Notices From April 9

The latest staffing, leadership and boardroom news from Michigan’s technology-focused business, institutions and groups.

WWJ Newsradio 950–2012/04/09

Esperion Announces Positive Phase 2 Clinical Trial Results for ETC-1002

Esperion Therapeutics, a privately held biotechnology company in Plymouth, Monday announced positive results from a Phase 2 clinical trial for its potential cholesterol buster, ETC-1002.

WWJ Newsradio 950–2012/03/26

Listen Live!